<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03689426</url>
  </required_header>
  <id_info>
    <org_study_id>CAR0540</org_study_id>
    <nct_id>NCT03689426</nct_id>
  </id_info>
  <brief_title>Using Cardiovascular Magnetic Resonance Tissue Characterisation and Wearable Technology to PREDICT Clinical Outcomes, Response to Therapy and Arrhythmias in Hospitalised Heart Failure Patients</brief_title>
  <acronym>PREDICT-HF</acronym>
  <official_title>Using Cardiovascular Magnetic Resonance Tissue Characterisation and Wearable Technology to Predict Clinical Outcomes, Response to Therapy and Arrhythmias in Hospitalised Heart Failure Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Southampton NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital Southampton NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      150 patients admitted to University Hospital Southampton with heart failure will undergo&#xD;
      comprehensive Cardiovascular Magnetic Resonance (CMR) imagining during their admission and&#xD;
      continuous heart rhythm monitoring using wearable technology post discharge.&#xD;
&#xD;
      We hypothesise that analysis of this outcome data will discover novel CMR tissue&#xD;
      characterisation and heart rhythm biomarkers that can be used to predict adverse clinical&#xD;
      outcomes in heart failure populations and how individual patients will respond to specific&#xD;
      therapies.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PREDICT-HF a low risk single centre observational study in which 150 consecutive patients&#xD;
      admitted with a new, primary diagnosis of heart failure undergo advanced CMR to&#xD;
      non-invasively establish their individual myocardial tissue characteristics during their&#xD;
      initial presentation.&#xD;
&#xD;
      All study participants will be invited to participate in an optional heart rhythm and rate&#xD;
      monitoring sub study which will involve continuous electrocardiographic monitoring for up to&#xD;
      2 days prior to discharge and up to 30 day immediately post discharge using a Samsung S-PATCH&#xD;
      device.&#xD;
&#xD;
      To enable multivariate statistical analysis to be performed each study participant will&#xD;
      undergo a range of validated investigation to comprehensively establish and monitor other&#xD;
      recognised heart failure prognostic biomarkers.&#xD;
&#xD;
      Participants will be managed per current NICE heart failure guidelines and will undergo&#xD;
      rigorous clinical reviews at 6, 12 and 24 months. All clinically relevant event data e.g.&#xD;
      MACE, rehospitalisation, decompensation and arrhythmias will be meticulously recorded for&#xD;
      each participant throughout the study period.&#xD;
&#xD;
      This study will identify novel CMR derived tissue characterisation biomarkers of adverse&#xD;
      outcome, response to therapy and arrhythmias in a hospitalised heart failure population. It&#xD;
      will also be the first study to utilise wearable heart monitoring technology to accurately&#xD;
      record heart rate and rhythm data in this population and investigate the potential impact of&#xD;
      this on patient's clinical management and outcomes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 30, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>All Cause Mortality</measure>
    <time_frame>2 years</time_frame>
    <description>Number of deaths within the study population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rehospitalisation with heart failure</measure>
    <time_frame>2 years</time_frame>
    <description>Number of Rehospitalisations with heart failure within the study population</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Cardiac arrythmia</measure>
    <time_frame>30 days</time_frame>
    <description>The number of any cardiac arrhythmia following discharge within the study population</description>
  </other_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Heart Failure</condition>
  <condition>Diffuse Fibrosis</condition>
  <condition>Focal Fibrosis</condition>
  <condition>Arrythmia</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, plasma and urine samples will be stored for future 'OMICS' analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients admitted to University Hospital Southampton with a new primary diagnosis of&#xD;
        heart failure will be considered for the study.&#xD;
&#xD;
        The diagnosis of heart failure will be confirmed by a senior cardiologist with a&#xD;
        subspecialty interest in heart failure following detailed review of the patient's history,&#xD;
        clinical findings and investigations using the following diagnostic criteria:&#xD;
&#xD;
          1. Signs and symptoms of heart failure&#xD;
&#xD;
             &amp;&#xD;
&#xD;
          2. Objective evidence of cardiac dysfunction either by;&#xD;
&#xD;
        Left ventricular ejection fraction of ≤ 50%&#xD;
&#xD;
        or;&#xD;
&#xD;
        Plasma concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) &gt;400 pg/mL if&#xD;
        in sinus rhythm or &gt; 1000 pg/ml if in atrial fibrillation/flutter and being treated with&#xD;
        either oral or intravenous furosemide ≥40 mg/day or equivalent at the time of inclusion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18&#xD;
&#xD;
          -  First hospital admission with a diagnosis of HF (as defined below)&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
          -  Able to undergo CMR&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known or subsequent diagnosis of amyloidosis, sarcoidosis or hypertrophic&#xD;
             cardiomyopathy&#xD;
&#xD;
          -  Severe valve disease of any type requiring inpatient surgery&#xD;
&#xD;
          -  Heart transplant recipient or admitted for cardiac transplantation/ left ventricular&#xD;
             assist device&#xD;
&#xD;
          -  Clinically apparent myocardial ischemia which requires revascularisation&#xD;
&#xD;
          -  Myocardial infarction or revascularisation within the previous 60 days&#xD;
&#xD;
          -  Intra cardiac mass which requires surgery&#xD;
&#xD;
          -  Active endocarditis&#xD;
&#xD;
          -  Septicaemia&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Life expectancy &lt;2 years secondary to any other cause (i.e. malignancy)&#xD;
&#xD;
          -  Active treatment with chemotherapy&#xD;
&#xD;
          -  Severe renal failure (GFR &lt;30)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Andrew Flett, MBBS MD(Res) MRCP BSc(Hons)</last_name>
    <phone>02381205906</phone>
    <email>andrew.flett@uhs.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Robert Adam, MBBS MRCP BSc(Hons)</last_name>
    <phone>02380777222</phone>
    <phone_ext>6744</phone_ext>
    <email>robert.adam@uhs.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital Southampton</name>
      <address>
        <city>Southampton</city>
        <state>Hampshire</state>
        <zip>SO166YD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Flett, MBBS MD(Res) MRCP BSc(Hons)</last_name>
      <phone>02381205906</phone>
      <email>andrew.flett@uhs.nhs.uk</email>
    </contact>
    <contact_backup>
      <last_name>Robert Adam, MBBS MRCP BSc(Hons)</last_name>
      <phone>02380777222</phone>
      <phone_ext>6744</phone_ext>
      <email>robert.adam@uhs.nhs.uk</email>
    </contact_backup>
    <investigator>
      <last_name>Andrew Flett, MBBS MD(Res) MRCP BSc(Hons)</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Robert Adam, MBBS MRCP BSc(Hons)</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 27, 2018</study_first_submitted>
  <study_first_submitted_qc>September 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2018</study_first_posted>
  <last_update_submitted>September 27, 2018</last_update_submitted>
  <last_update_submitted_qc>September 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cardiovascular Magnetic Resonance Imaging</keyword>
  <keyword>Tissue Characterisation</keyword>
  <keyword>Wearable Technology</keyword>
  <keyword>Prognosis</keyword>
  <keyword>Response to Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Arrhythmias, Cardiac</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

